CA2471127A1 - Methode anti-sens de modulation de la reponse des recepteurs d'oestrogenes (er.alpha. et/ou er.beta.) - Google Patents
Methode anti-sens de modulation de la reponse des recepteurs d'oestrogenes (er.alpha. et/ou er.beta.) Download PDFInfo
- Publication number
- CA2471127A1 CA2471127A1 CA002471127A CA2471127A CA2471127A1 CA 2471127 A1 CA2471127 A1 CA 2471127A1 CA 002471127 A CA002471127 A CA 002471127A CA 2471127 A CA2471127 A CA 2471127A CA 2471127 A1 CA2471127 A1 CA 2471127A1
- Authority
- CA
- Canada
- Prior art keywords
- antisense oligonucleotide
- seq
- beta
- antisense
- estradiol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne de nouveaux oligonucléotides anti-sens ciblant les gènes et les ARNs messagers codant pour les récepteurs d'oestrogènes (ER) alpha et/ou bêta mammifères et modulant les réponses des récepteurs. Ces oligonucléotides anti-sens peuvent être utilisés seuls ou en combinaison avec le 17 bêta oestradiol ou un composé associé (génistéine, dérivés d'oestradiol...) afin d'améliorer la stabilisation des plaques, la cicatrisation vasculaire et la récupération endothéliale suite à une lésion vasculaire. L'invention concerne également des méthodes de conception et d'essai des oligonucléotides anti-sens. Ces oligonucléotides peuvent être utilisés pour moduler les effets bénéfiques associés aux récepteurs d'oestrogènes sur la cicatrisation vasculaire, par exemple, la resténose ou la stabilisation des plaques, chez les mammifères. La présente invention concerne en outre des compositions et des formulations pharmaceutiques comprenant les nouveaux oligonucléotides anti-sens de la présente invention, et destinées à être utilisées dans le traitement des mammifères atteints d'une maladie ou de troubles caractérisés par l'athérosclérose, la vulnérabilité ou la déstabilisation des plaques ou une rupture ou l'usure pathologique des plaques, y compris une lésion spontanée ou provoquée.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002471127A CA2471127A1 (fr) | 2001-12-21 | 2002-12-20 | Methode anti-sens de modulation de la reponse des recepteurs d'oestrogenes (er.alpha. et/ou er.beta.) |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002365811A CA2365811A1 (fr) | 2001-12-21 | 2001-12-21 | Nouvelle therapie genique utilisant la strategie anti-sens pour les recepteurs estrogeniques (er .alpha. et/ou er .beta.) afin d'optimiser la regeneration vasculaire et la cardioprotection a la suite d'une lesion va sculaire |
| CA2,365,811 | 2001-12-21 | ||
| CA002471127A CA2471127A1 (fr) | 2001-12-21 | 2002-12-20 | Methode anti-sens de modulation de la reponse des recepteurs d'oestrogenes (er.alpha. et/ou er.beta.) |
| PCT/CA2002/002000 WO2003056010A2 (fr) | 2001-12-21 | 2002-12-20 | Methode anti-sens de modulation de la reponse des recepteurs d'oestrogenes (er $g(a) et/ou er $g(b)) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2471127A1 true CA2471127A1 (fr) | 2003-07-10 |
Family
ID=33098714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002471127A Abandoned CA2471127A1 (fr) | 2001-12-21 | 2002-12-20 | Methode anti-sens de modulation de la reponse des recepteurs d'oestrogenes (er.alpha. et/ou er.beta.) |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2471127A1 (fr) |
-
2002
- 2002-12-20 CA CA002471127A patent/CA2471127A1/fr not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7235534B2 (en) | Antisense strategy to modulate estrogen receptor response (ER α and/or ER β ) | |
| JP6991966B2 (ja) | Ｌｐａの遺伝子発現の阻害のための組成物及び方法 | |
| EP2850186B1 (fr) | Compositions et procédés de modulation de l'expression de la famille génique smn | |
| US20030186920A1 (en) | Antisense oligonucleotide directed toward mammalian vegf receptor genes and uses thereof | |
| JP4486365B2 (ja) | アンチセンスｉａｐ核酸塩基オリゴマーおよびその使用 | |
| JP2015523853A (ja) | Ａｔｐ２ａ２発現を調節するための組成物及び方法 | |
| EP0871494A1 (fr) | Compositions et methodes pour le traitement des cellules tumorales | |
| JP2002526125A (ja) | 腫瘍壊死因子−α（ＴＮＦ−α）発現のアンチセンス・オリゴヌクレオチド調節 | |
| JP2002526093A (ja) | ｂｃｌ−ｘ発現のアンチセンスモジュレーション | |
| JP2015518712A (ja) | Ｍｅｃｐ２発現を調節するための組成物及び方法 | |
| JP2015518710A (ja) | ヘモグロビン遺伝子ファミリー発現を調節するための組成物及び方法 | |
| US20050153921A1 (en) | Methods of using mammalian RNase H and compositions thereof | |
| JP2002526095A (ja) | 腫瘍壊死因子受容体関連因子（ｔｒａｆ）の発現のアンチセンスモジュレーション | |
| WO2004092379A9 (fr) | Methode de traitement de troubles angiogeniques | |
| US20040220131A1 (en) | Method for treatment of cancerous angiogenic disorders | |
| EP1597365A1 (fr) | Oligonucleotides antisens se dirigeant vers la ribonucleotide reductase r2 et son utilisation dans le traitement du cancer | |
| KR101783444B1 (ko) | miR-33-5p 를 이용한 뇌신경세포 보호 물질 스크리닝 방법 | |
| CA2471127A1 (fr) | Methode anti-sens de modulation de la reponse des recepteurs d'oestrogenes (er.alpha. et/ou er.beta.) | |
| US7465714B2 (en) | Oligonucleotide inhibitors of MBD2/DNA demethylase and uses thereof | |
| Le Corre et al. | Critical issues in the antisense inhibition of brain gene expression in vivo: Experiences targetting the 5-HT1A receptor | |
| US20040248145A1 (en) | Methods of using mammalian RNase H and compositions thereof | |
| WO2007139943A2 (fr) | Combinaisons et systèmes de délivrance de médicaments thérapeutiques comprenant des polynucléotides anti-sens de la c-raf kinase destinés au traitement des maladies et affections oculaires | |
| US20050164234A1 (en) | Methods of using mammalian RNase H and compositions thereof | |
| US20050065065A1 (en) | Modulation of the expression of estrogen receptors for the prevention or treatment of heart disease | |
| EP1453849A2 (fr) | Modulation antisens du recepteur de la purine p2x sb 3 /sb |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |